Boston Scientific Corporation vs SoundHound AI Inc — how do they compare? Boston Scientific Corporation trades at $43.36 (market cap $66.37B), while SoundHound AI Inc trades at $6.49 (market cap $2.91B). The key difference: Boston Scientific Corporation is far larger — about 22.8× SoundHound AI Inc's market cap. Which is the better fit depends on your goals.
| BSX | SOUN | |
|---|---|---|
Market Cap | $66.37B | $2.91B |
Sector | Health | Technology |
52-Week High | $108.14 | $21.40 |
52-Week Low | $42.63 | $5.90 |
Enterprise Value | $75.94B | $2.71B |
Signals from Pluang's Aura AI — not financial advice
Boston Scientific (BSX) trades at $44.65, down 0.27% with bearish technical signals despite strong fundamentals. The company delivered three consecutive earnings beats with Q3-Q1 2026 EPS exceeding expectations, while revenue grew to $20.07B in 2025 with improving profit margins. Technical indicators show bearish momentum with support at $44 and resistance at $45, though Wall Street maintains 88% buy rating with $70.20 consensus target.
BSX presents a compelling value opportunity with attractive valuation multiples (P/E 18.68, P/S 3.24) and robust financial health, though near-term headwinds include competitive pressures in key segments and recent stock price decline of nearly 60% from 2025 highs. The strong analyst consensus suggests significant upside potential if execution improves.
SoundHound AI (SOUN) trades at $6.49, down 2.26% on the day and 37% year-to-date, reflecting investor concerns over persistent losses despite strong revenue growth. The stock shows a bearish technical trend with neutral oscillators, while fundamentals reveal a high P/S of 15.03 and negative net income margin of -91.84%. Recent positive developments include being named a Leader in Gartner's Magic Quadrant for Conversational AI Platforms (GlobeNewsWire, July 13, 2026) and beating EPS estimates in three consecutive quarters.
The outlook remains high-risk with significant cash burn and execution challenges, but analyst consensus is bullish with a $13 price target (75% buy ratings). Investment opportunity hinges on successful integration of acquisitions like LivePerson and expansion into telecom/energy markets, though volatility from short interest and profitability concerns pose substantial downside risk.
Trailing returns across standard periods
Latest headlines on both assets
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →SoundHound AI, Inc. is a leading innovator in voice artificial intelligence, specializing in conversational intelligence technology. The company develops a platform that allows businesses to add custom voice assistants and natural language processing capabilities to their products and services, ranging from in-car systems and smart speakers to mobile apps and IoT devices. SoundHound's core technology, including its proprietary speech recognition and natural language understanding models, aims to enable fast, accurate, and deeply integrated voice AI experiences across various industries.
Read more on SOUN →